Fractyl Health, Inc. (NASDAQ:GUTS) Sees Significant Growth in Short Interest

Fractyl Health, Inc. (NASDAQ:GUTS) was the target of a significant increase in short interest during the month of September. As of September 30th, there was short interest totalling 1,870,000 shares, an increase of 61.2% from the September 15th total of 1,160,000 shares. Based on an average trading volume of 356,500 shares, the short-interest ratio is presently 5.2 days. Currently, 9.4% of the company’s shares are sold short.

Insider Transactions at Fractyl Health

In other Fractyl Health news, insider Jay David Caplan sold 65,000 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $2.90, for a total transaction of $188,500.00. Following the completion of the sale, the insider now owns 30,484 shares in the company, valued at approximately $88,403.60. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Institutional Trading of Fractyl Health

A number of hedge funds have recently made changes to their positions in the business. M28 Capital Management LP acquired a new stake in shares of Fractyl Health during the 1st quarter worth about $13,735,000. American International Group Inc. bought a new stake in shares of Fractyl Health during the first quarter worth approximately $9,911,000. Massachusetts Financial Services Co. MA grew its position in shares of Fractyl Health by 2.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 996,383 shares of the company’s stock valued at $4,255,000 after purchasing an additional 25,829 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Fractyl Health during the second quarter worth approximately $61,000. Finally, SG Americas Securities LLC acquired a new stake in Fractyl Health during the 3rd quarter worth approximately $33,000.

Fractyl Health Stock Performance

Shares of GUTS traded down $0.04 during mid-day trading on Monday, hitting $2.42. 145,139 shares of the company’s stock were exchanged, compared to its average volume of 305,168. The company has a 50-day simple moving average of $2.69 and a 200 day simple moving average of $4.69. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.46 and a quick ratio of 7.46. Fractyl Health has a 52 week low of $1.74 and a 52 week high of $14.50.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.10. The company had revenue of $0.04 million during the quarter. On average, equities research analysts anticipate that Fractyl Health will post -1.61 EPS for the current fiscal year.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.